Abstract | BACKGROUND: At present the addition of thoracic irradiation to combination chemotherapy is a standard treatment for limited staged small cell lung cancer. However, there is still controversy about the optimum timing of chest irradiation. We conducted a phase II study of etoposide (VP-16)-ifosfamide-cisplatin ( VIP) combination chemotherapy plus early concurrent thoracic irradiation for the patients with previously untreated limited small cell lung cancer in order to assess if the treatment modality could improve the response rate and the toxicity. METHODS: RESULTS: Forty-four of the 49 patients who entered the study from May 1994 to August 1998 were evaluable. The median age was 59 years and 40 patients had a performance status of 0 or 1. The median survival time was 22.5 months. Twenty-eight patients (62%) showed a complete response and 16 (38%) a partial response. Twenty-four patients (54%) developed grade 3 or 4 neutropenia; there was a 9% RTOG score 3 or 4 esophagitis. CONCLUSION:
|
Authors | I S Woo, Y S Park, S H Kwon, Y L Park, J A Lee, M J Park, I G Hyun, K S Jung, H S Bae, D H Oh, W S Kim, K Park, C H Park, H J Kim, Y C Ahn |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 30
Issue 12
Pg. 542-6
(Dec 2000)
ISSN: 0368-2811 [Print] England |
PMID | 11210163
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Etoposide
- Cisplatin
- Ifosfamide
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Small Cell
(drug therapy, radiotherapy)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Drug Administration Schedule
- Etoposide
(administration & dosage)
- Female
- Humans
- Ifosfamide
(administration & dosage)
- Lung Neoplasms
(drug therapy, radiotherapy)
- Male
- Middle Aged
- Survival Analysis
- Thorax
(radiation effects)
|